Bristol-Myers Squibb (NY: BMY )

59.49 USD +1.24 (+2.13%)

Official Closing Price Updated: 7:38 PM EDT, Sep 25, 2020 Add to My Watchlist

Price and Volume

Volume	9,835,900
Open	58.26
Bid (Size)	59.20 (1)
Ask (Size)	59.50 (30)
Prev. Close	58.25
Today's Range	58.16 - 59.84
52wk Range	45.76 - 68.34
Shares Outstanding	1,634,538,458
Dividend Yield	2.69%

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Opdivo (nivolumab) Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial

September 24, 2020

Opdivo Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial.....

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)

September 22, 2020

FDA Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel....

Performance

YTD	-6.08%	-6.08%
1 Month	-4.48%	-4.48%
3 Month	+3.39%	+3.39%
6 Month	+12.69%	+12.69%
1 Year	+19.05%	+19.05%

More News

ROCE Insights For Bristol-Myers Squibb

September 25, 2020

Bristol Myers Squibb Completes Acquisition of Forbius

September 21, 2020

Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo in the Adjuvant Setting

September 21, 2020

6 Stocks Moving In Thursday's After Hours Session

September 24, 2020

Opdivo (nivolumab) Plus Chemotherapy Demonstrated Significant Overall and Progression-Free Survival Benefits Versus Chemotherapy in First-Line Treatment of Gastric and Esophageal Cancers

September 21, 2020

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial

September 19, 2020

73 Firms Going Ex-Dividend Next Week, Including Cardinal Health, Realty Income And Cisco Systems

September 25, 2020

June 2021 Options Now Available For Bristol-Myers Squibb (BMY)

September 23, 2020

10 Biggest Price Target Changes For Tuesday

September 22, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.